Home About Us Pipeline News Investors Contacts Careers

STOCK INFORMATION

FEATURED PRESS RELEASE

  • 7/22/14 1:20 pm PDT

    Neratinib Achieves Statistically Significant Improvement in Disease Free Survival

    Company Plans to File for Regulatory Approval in First Half of 2015

    LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced top line results from the Phase III clinical trial of Puma's investigational drug PB272 (neratinib) for the extended adjuvant treatment of breast cancer (ExteNET Trial). The ExteNET trial is a double-blind, placebo-controlled, Phase III trial of neratinib versus placebo after adjuvant treatment with trastuzumab (Herceptin) in women with early stagemore...

SEARCH INVESTOR RELATIONS

CONTACTS

Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax

ir@pumabiotechnology.com